Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

COALA Study

COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic trial (COALA-2) (Trial registration pending)

Currently recruiting

COALITION

A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL) (COALITION) (NCT04914741)

No longer recruiting

COBRRA

COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism (COBRRA) (NCT03266783)

Currently recruiting

Codebreak-202 20190341

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (NCT05920356)

Currently recruiting

COGENT

D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT): A Multi-Site, Randomised, Placebo-Controlled Trial (ACTRN12622001359729)

Currently recruiting

COLLIGO

mavaCamten Observational evidence Global cOnsortium in HCM [COLLIGO-HCM] (NCT06372457)

The aim of this study is to investigate treatments and real-world effectiveness for hypertrophic cardiomyopathy (HCM), including examining the path to diagnosis, disease progression, and the new treatment for obstructive HCM (o-HCM), mavacamten. This protocol localisation for COLLIGO-HCM is for The Alfred Hospital participating site in Australia. It will address only a subset of the objectives from the master protocol which were deemed applicable after conducting feasibility.
Currently recruiting

COMB157GAU01

Secondary use of data study characterizing Kesimpta (ofatumumab) onboarding and utilization in RMS patients using MSGo, with a non-interventional primary use of data sub-study comparing Patient Reported Outcomes relative to Clinical Outcomes (EAFToS) (NCT05090033)

No longer recruiting

CONNEX X

An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEXX) (NCT05211947)

Currently recruiting

CONNEX-1

A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1) (NCT04846868)

Currently recruiting

CORE

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (NCT05079919)

No longer recruiting

CorSky

BIO|CONCEPT.CorSky Family (NCT05610176)

Currently recruiting

COSTAR

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in With Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti-PD(L)1 Therapy and Chemotherapy (NCT04655976)

No longer recruiting

CP-AU-007-01

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer (NCT05267626)

Currently recruiting

CP-MVC-101-01

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT04844073)

Currently recruiting

CPHE885B12201

A Phase 2 Study of PHE885, a BCMA-directed CAR-T Cell Therapy for Patients with Relapsed and Refractory Multiple Myeloma (NCT05172596)

Currently recruiting

CROSSING

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) (NCT05583227)

Currently recruiting

CRSP-ONC-006

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT05643742)

Currently recruiting

CRSP-ONC-LTF

A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies (NCT06208878)

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies.
Coming soon

CRVOMed Study

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery after Ischemic Stroke (NCT06987643)

Currently recruiting

CS2009

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors (NCT06741644)

Currently recruiting
7 8 9 10 11